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Objectives This prospective cohort study in patients with aortic stenosis (AS) aimed to identify surrogates of myocardial fi-
brosis that are easy to derive in clinical practice, allow the differentiation of low-gradient severe AS from moder-
ate AS, and have an impact on clinical outcome.
Background In patients with symptomatic aortic AS, a characteristic subgroup (i.e., up to one-third) exhibits severe AS with a
concomitant low mean valve gradient either with preserved or reduced ejection fraction (EF). It is hypothesized
that these patients tend to have an advanced stage of myocardial fibrosis and poor clinical outcome.
Methods Eighty-six patients with moderate or severe AS were examined by echocardiography including conventional aortic
valve assessment, mitral ring displacement, and strain-rate imaging. Replacement fibrosis was quantified by
late-enhancement magnetic resonance imaging. Biopsy samples were taken from patients with severe AS
(n  69) at aortic valve replacement. All patients were followed for 9 months.
Results Patients were divided into 4 groups according to aortic valve area (1.0 cm2), mean valve gradient 40 mm
Hg, and EF (50%): group 1, moderate AS (n  17); group 2, severe AS/high gradient (n  49); group 3, severe
AS/low gradient/preserved EF (n  11); and group 4, severe AS/low gradient/decreased EF (n  9). At baseline,
a significant decrease in mitral ring displacement and systolic strain rate was detected in patients with low-
gradient AS. In low-gradient groups, a higher degree of interstitial fibrosis in biopsy samples and more late-
enhancement magnetic resonance imaging segments were observed. A close inverse correlation was found be-
tween interstitial fibrosis and mitral ring displacement (r  0.79, p  0.0001). Clinical outcome was best for
patients in group 1, whereas mortality risk increased substantially in groups 2 through 4.
Conclusions In severe AS, a low gradient is associated with a higher degree of fibrosis, decreased longitudinal function,
and poorer clinical outcome despite preserved EF. Mitral ring displacement differentiates between moder-
ate AS and low-gradient/severe AS with preserved EF. (J Am Coll Cardiol 2011;58:402–12) © 2011 by the
American College of Cardiology FoundationIn patients with symptomatic aortic valve stenosis (AS), a
characteristic subgroup (i.e., as many as one-third of pa-
tients) exhibits severe AS with a concomitant low mean
valve gradient either with preserved or decreased ejection
fraction (EF). It is well known that patients with severe AS
may present with a low gradient if their EF and cardiac
output are decreased. Moreover, recent studies suggest that
an important proportion of the patients with severe AS may
paradoxically have a low transvalvular flow rate despite the
presence of a preserved EF (1). The decrease in left
ventricular (LV) output may then result in lower than
expected transvalvular gradients. This disease pattern may
potentially lead to an underestimation of stenosis and
symptom severity and thus to inappropriate delay of aortic
valve replacement (AVR), which may, in turn, have a
negative impact on patient outcome (1,2). These patients
represent the most challenging category with respect to
appropriate diagnostic and therapeutic management (1).
See page 413
To date, pre-operative clinical symptoms and echocar-
diographic markers for the determination of the severityof AS provide little prognostic information on cardiac
function recovery and clinical outcome after AVR. Thus,
EF is dependent on LV geometry and markedly under-
estimates the extent of myocardial dysfunction in the
presence of severe concentric myocardial hypertrophy, as
often encountered in patients with AS with a small LV
cavity (3–7). Recent studies proved that patients with a
normal EF but a decreased mean transvalvular gradient
have a significantly higher afterload, and the EF does not
satisfactorily reflect LV performance under these partic-
ular circumstances (1). Importantly, LV pressure over-
load due to long-standing afterload excess induces myo-
cardial fibrosis, affecting mainly the subendocardial
layers, which are thought to be predominantly responsi-
ble for longitudinal function and not well reflected by
global EF (3,8). To date, it remains unknown whether
and how LV remodeling toward fibrosis affects LV
function and clinical outcome after AVR in patients with
low-gradient AS. Therefore, the objectives of the present
clinical study in patients with isolated AS were: 1) to
describe global and longitudinal LV function in groups
with different transvalvular gradients; 2) to compare LV
structure abnormalities (i.e., myocardial fibrosis), hemo-
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Myocardial Fibrosis in Low-Gradient Aortic Valve Stenosis July 19, 2011:402–12dynamics, and function in the
different groups; 3) to evaluate
clinical outcome in relation to
transvalvular gradients; and,
most importantly, 4) to define
an easily assessable LV func-
tional parameter that may help
to distinguish between moder-
ate AS and severe AS with a
low-gradient and preserved EF
in clinical routine.
Methods
Study population. In total, 130
consecutive patients with moder-
ate to severe AS (referred from
general practice or specialist out-
patient clinics) were screened,
and 86 patients were included in
the final dataset. Patients were
included if they had either iso-
lated severe AS with symptoms
on exertion and an aortic valve
area (AVA) 1.0 cm2 or moderate AS defined as an AVA
1.5 and 1.0 cm2. The reasons for exclusion were a
history of myocardial infarction as well as significant coro-
nary artery disease (degree of vessel stenosis 50%), un-
cured cancer, and other moderate or severe valvular dysfunc-
tion. Five patients were excluded solely on the basis of heart
catheterization showing a vessel stenosis 50%. Some of
the data have already been analyzed previously by studying
the impact of fibrosis in high-gradient AS (8). All patients
with severe AS were referred for surgery.
Baseline Characteristics of the SubgroupsTable 1 Baseline Characteristics of the Subgroups
Moderate AS
(n  17)
Seve
Age, yrs 77 8
Male/female 8/9
Blood pressure systolic, mm Hg 141 19
Systemic vascular resistance, mm Hg·min·l1 2,109 745
Systemic arterial compliance, ml·mm Hg1·m2 0.70 0.1
NYHA functional classes I/II/III/IV 8/8/1/0
Angina 5 (29)
Syncope 0 (0)
Atrial fibrillation 3 (18)
History of hypertension 14 (82)
Diabetes mellitus 5 (30)
Hyperlipoproteinemia 10 (58)
Current smoking 3 (18)
EuroScore, % 11.1 11
Abbreviations
and Acronyms
AS  aortic stenosis
AUROC  area under the
receiver-operator
characteristic curve
AVA  aortic valve area
AVR  aortic valve
replacement
CI  confidence interval
cMRI  cardiac magnetic
resonance imaging
EF  ejection fraction
LE  late enhancement
LV  left ventricular
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
NYHA  New York Heart
Association
OR  odds ratio
PIIINP  procollagen type
III amino terminal peptideValues are mean  SD, n, or n (%). *p  0.05 versus moderate AS. †p  0.05 versus severe AS/high gr
AS  aortic stenosis; EF  ejection fraction; NYHA  New York Heart Association.Study protocol. In the context of pre-operative manage-
ment, all patients with severe AS underwent cardiac heart
catheterization and cardiac magnetic resonance imaging
(cMRI) with late-enhancement (LE) imaging for replace-
ment fibrosis within 2 weeks. In patients with a reduced EF
(n  6), low-dose dobutamine stress echocardiography was
performed to confirm true severe AS. Within the next 3
weeks, AVR was performed in all patients with severe AS,
and 2 endomyocardial biopsy samples were taken from the
endocardium of the basal LV septum (for interstitial fibro-
sis). Nine months after the baseline assessment, a clinical
follow-up examination including conventional echocardiog-
raphy and strain-rate imaging was performed in all patients.
In addition, in the group of patients who had undergone
AVR, follow-up cMRI was performed. The study was
reviewed and approved by the local ethics committee of
University Hospital Würzburg and was conducted accord-
ing to the principles outlined in the Declaration of Helsinki.
Informed consent was obtained from all patients before any
investigation.
Heart catheterization. All patients with severe AS un-
derwent standard heart catheterization before enrollment
in the study. LV pressure was recorded using fluid-filled
pigtail catheters after retrograde passage of the aortic
valve. Using a venous approach, right heart catheteriza-
tion was done with a Swan-Ganz catheter.
Standard echocardiography. Transthoracic echocardiog-
raphy was performed using the Vivid 7 System (GE
Vingmed Ultrasound, Horten, Norway) with a 3.5-MHz
transducer. A standard echocardiographic study for systolic
and diastolic parameters was done. Using established pa-
rameters for the assessment of AS severity, patients were
characterized and grouped by AVA, transvalvular mean
gradients and LVEF (9,10).
High Gradient
49)
Severe AS, Low Gradient,
EF >50%
(n  11)
Severe AS, Low Gradient,
EF <50%
(n  9)
 8* 75 4† 73 6
/16 3/8 5/4
 16* 130 20 128 24
9 61 3,912 890*† 3,760 695*†
 0.2 0.58 0.2 0.52 0.1*†
35/6* 0/0/8/3* 0/0/4/5*
(59)* 5 (45)* 7 (77)*
(10) 1 (9) 2 (22)
(10) 3 (27) 3 (33)
(89) 10 (90) 8 (89)
(20) 1 (9) 3 (27)
(51) 7 (63) 6 (67)
(26) 2 (18) 4 (44)
 7 20.3 15† 37.7 28†‡re AS
(n 
68
33
123
1,76
0.72
0/8/
29
5
5
44
10
25
13
8.7adient. ‡p  0.05 versus severe AS/low-gradient AS/EF 50%.
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July 19, 2011:402–12 Myocardial Fibrosis in Low-Gradient Aortic Valve StenosisAll patients were categorized into 1 of 4 groups: group 1,
moderate AS (n  17), AVA 1.0 cm2; group 2, severe
AS/high gradient (n  49), AVA 1.0 cm2  gradient
40 mm Hg; group 3, severe AS/low-gradient/preserved
EF (n 11), AVA1.0 cm2 gradient40 mmHg EF
50%; group 4, severe AS/low-gradient/reduced EF (n  9),
VA 1.0 cm2  gradient 40 mm Hg  EF 50%.
LV mass was computed by the Devereux modified cube
formula and normalized for body surface area to obtain the
LV mass index. LV hypertrophy was defined as LV mass
index 115 g/m2 in men and 95 g/m2 in women (11). In
ddition, LV wall stress (with the modified La Place
ormula, relative wall thickness (twice the diastolic posterior
all thickness divided by LV end-diastolic diameter), mid-
all fractional shortening, valvuloarterial impedance (Zva 
SAP  MG/SVI, where SAP is the systolic arterial pres-
Baseline Echocardiography of the SubgroupsTable 2 Baseline Echocardiography of the Subgroups
Moderate AS
(n  17)
Seve
Echocardiography (aortic stenosis severity)
Aortic valve area, cm2 1.4 0.3
Indexed aortic valve area, cm2·m2 0.79 0.16
Dimensionless velocity ratio 0.50 0.08
Peak aortic velocity, m·s1 2.9 0.5
Mean aortic gradient, mm Hg 21 8
Maximal aortic gradient, mm Hg 35 13
Valvular resistance, dyne·s·cm5 149 69
Calcification score 2.3 0.49
Index of global hemodynamic load
Valvuloarterial impedance, mm Hg·ml1·m2 4.1 1.4
Echocardiography (systolic parameters)
Ejection fraction, % 64 8
Stroke volume, ml 76 7
Stroke volume index, ml·m2 44 15
Transvalvular flow rate, ml·s1 252 28
Meridional end-systolic wall stress, kdyne·cm2 30 11
Mitral ring displacement, mm 12.8 1.7
Systolic pulmonary arterial pressure, mm Hg 29 9
Radial strain rate, s1 2.2 0.4
Septal longitudinal strain rate, s1 1.3 0.2
Echocardiography (diastolic parameters)
Deceleration time, ms 263 (219–280)
E/A 0.9 (0.7–0.9)
E/E= 13 (10–15)
Stage of diastolic function: normal/abnormal/
relaxation/pseudonormal/restrictive/
not determinable due to atrial fibrillation, %
6/63/11/0/20
Echocardiography (LV geometry)
Left ventricular end-systolic diameter, mm 31 6
Left ventricular end-diastolic diameter, mm 48 7
Posterior wall thickness  end-diastolic, mm 11 1.1
LV mass index, g·m2 132 37
Relative wall thickness 0.43 0.04Values are mean  SD, median (25th to 75th percentile), or %. *p  0.05 versus moderate AS. †p  0.
LV  left ventricular; other abbreviations as in Table 1.ure, MG is the mean gradient, and SVI is the stroke
olume index), stroke volume, systemic vascular and valvular
esistance, and arterial compliance were assessed (1). Val-
ular calcium score was assessed in the parasternal short axis
nd scaled as described by Rosenhek et al. (12).
Systolic mitral ring displacement was measured at the
eptal and lateral sides using M-mode echocardiography
n an apical 4-chamber view. For the final dataset, the
verage of these 2 measurements was used. The repro-
ucibility of this marker was examined by triple (intrao-
server) and double measurement (interobserver) of 10
ifferent patients, yielding coefficients of variation of
.5% and 6.3% for intraobserver and interobserver repro-
ucibility, respectively.
train rate imaging. Tissue Doppler imaging was done
mmediately after conventional echocardiography and post-
, High Gradient
 49)
Severe AS, Low Gradient,
EF >50%
(n  11)
Severe AS, Low Gradient,
EF <50%
(n  9)
 0.2* 0.8 0.2* 0.8 0.1*
 0.07* 0.44 0.07*† 0.41 0.1*
 0.05* 0.28 0.07* 0.28 0.08*
 0.5* 3.7 0.5*† 3.4 0.5*†
 11* 33 7*† 29 8*†
 18* 59 11*† 47 12†
 148* 356 178* 306 64*
 0.50* 3.0 0.61* 3.2 0.62*
 1.5 8.2 2.0*† 8.9 1.2*†
 9* 61 5 36 10*†‡
 9 44 5*† 43 9*†
 9 28 4*† 27 5*†
 30 113 35*† 118 20*†
 18 42 15 58 21*†‡
 2.4* 5.8 1.1*† 5.0 0.9*†
 12 33 12 36 14
 0.3* 1.7 0.3* 1.4 0.2*†‡
 0.3* 0.6 0.2*† 0.6 0.2*†
193–360) 326 (262–373) 247 (184–310)
0.7–1.1) 0.8 (0.6–0.9) 1.1 (0.7–1.2)
12–20) 24 (15–27)* 21 (18–20)*
/18/8/11 0/54/9/9/28 0/33/22/11/66
 9 31 7 42 7*†‡
 8 45 6 56 5*‡
 1.4* 13 1.6* 13 1.0*
 53* 162 39 197 35*
 0.1* 0.58 0.1* 0.44 0.08†‡re AS
(n
0.8
0.39
0.25
4.5
57
86
455
3.4
5.0
55
75
38
250
37
9.4
33
1.7
1.1
269 (
1.1 (
18 (
0/63
34
50
14
195
0.5605 versus severe AS/high gradient. ‡p  0.05 versus severe AS/low-gradient AS/EF 50%.
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Ultrasound). Radial function was assessed by peak systolic
strain rate (related to regional contractility) scanning the
posterior wall from parasternal views. For longitudinal
function, this parameter was extracted from the mid-
ventricular segment of the septum and lateral wall using an
apical 4-chamber view.
Cardiac magnetic resonance imaging. In patients with
severe AS and without contraindications (n  46), cine
cMRI and LE imaging were performed using a 1.5-T
magnetic resonance scanner to determine myocardial re-
placement fibrosis. To detect LE, short-axis images were
acquired 10 to 15 min after injection of gadopentetate
dimeglumine (0.2 mmol/kg of body weight, Magnevist,
Schering, Berlin, Germany) using an inversion recovery
sequence (field of view, 240  320 mm2; matrix, 165 
256). Each of the 17 LV segments was assessed for the
presence or absence of LE (i.e., replacement fibrosis) by an
experienced radiologist who was blinded to patient out-
come, degree of fibrosis on endomyocardial biopsy samples,
and time sequence of scans.
Grading of endomyocardial biopsy samples. Biopsy sam-
ples were taken during AVR from the basal septum. The
percentage of the area of fibrosis was calculated by an experi-
enced pathologist and used as the index of the degree of fibrosis
(8). The percentage of area of fibrosis in the section was
btained by dividing the sum of the fibrotic areas of the section
y the total tissue area, as described by Tanaka et al. (13). In
Baseline Left Heart Catheterization, Magnetic Resonance Imaging,Table 3 Baseline Left Heart Catheterization, Magnetic Resona
Severe AS, High
(n  49
Left heart catheterization
Aortic valve area, cm2 0.7 0.1
Indexed aortic valve area, cm2·m2 0.39 0.1
Pulmonary capillary wedge pressure, mm Hg 14 7
Stroke volume, ml 72 12
Stroke volume index, ml·m2 40 5
Mean aortic pressure gradient, mm Hg 53 8
Transvalvular flow rate, ml/s 241 40
Central venous oxygen saturation, % 69 4
cMRI
Ejection fraction, % 55 13
Late enhancement–positive segments: 0/1/1, % 47/19/3
Myocardial histology
Interstitial fibrosis, % 1.8 0.8
Myocyte diameter, m 12.2 1.3
Cardiac biomarkers
NT-proBNP, pg/ml 1,418 (377–1
PIIINP, g/ml 3.4 0.8
Values are mean  SD, %, or median (25th to 75th percentile). *p  0.05 versus severe AS/high
cMRI  cardiac magnetic resonance imaging; NT-proBNP  N-terminal pro–B-type natriuretic pddition, fiber diameters were measured (8). uata analysis. Data are presented as mean  SD or
edian (quartiles) or frequency (percentage), as appro-
riate. The chi-square test, Fisher exact test, or Mann-
hitney U test was used to compare categories, as
ppropriate. Statistical testing was done for purely de-
criptive reasons; hence, no adjustment for multiple
esting was implemented. Correlations were computed
sing Spearman’s correlation coefficient. p value for trend
as computed using analysis of variance after checking
he assumption of homogeneity of variances. Two sets of
ogistic regression analyses were run to investigate 2
ependent variables: fibrosis (yes vs. no) and no improve-
ent in New York Heart Association (NYHA) func-
ional class or death (yes vs. no). Fibrosis was considered
resent if the fibrosis score was 2%. Functional im-
rovement was accepted if a patient had improved at least
NYHA functional class at follow-up. For both sets, the
iagnostic/prognostic performance of biomarkers (pro-
ollagen type III amino-terminal peptide [PIIINP],
-terminal pro–B-type natriuretic peptide [NT–proBNP],
nd mitral ring displacement) was qualitatively compared
nd the odds ratio (OR) with its 95% confidence interval
CI), Wald index, and the area under the receiver-operator
haracteristic curve (AUROC) (with its SE) were reported.
T-proBNP entered analyses as quartiles, and a linear
rend across categories was reported. These analyses were
erformed with fixed adjustment for sex and age. Further, in
multivariable logistic regression approach, independent
orrelates/predictors were sought by backward selection
cardial Histology, and Cardiac Biomarkersmaging, Myocardial Histology, and Cardiac Biomarkers
nt
Severe AS, Low Gradient,
EF >50%
(n  11)
Severe AS, Low Gradient,
EF <50%
(n  9)
0.7 0.2 0.8 0.1
0.41 0.14 0.46 0.11
15 7 18 7
56 13 63 13
31 4 34 3
37 8* 27 8*†
179 30* 184 20*
63 4* 59 4*†
56 12 38 17*†
0/20/80 0/23/77
3.9 0.6* 4.8 0.6*
13.1 1.5 13.7 1.3*
3,730 (1,858–5,671)* 5,016 (4,182–5,704)*
4.6 0.4 5.0 1.3*
nt. †p  0.05 versus severe AS/low gradient/EF >50%.
PIIINP  procollagen type III amino terminal peptide; other abbreviations as in Table 1.Myonce I
Gradie
)
2
4
,505)
gradiesing the likelihood ratio criterion (pin  0.05, pout  0.1).
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July 19, 2011:402–12 Myocardial Fibrosis in Low-Gradient Aortic Valve StenosisBecause of the small sample size, only the following vari-
ables were tested: EF, stroke volume, strain rate, mitral ring
displacement, AVA, NT-proBNP, PIIINP, and LE. All
tests were performed 2-sided. SPSS version 17.0.1 (SPSS
Inc., Chicago, Illinois) was used.
Results
Table 1 provides baseline clinical data for the 4 groups. Risk
actors and comorbidity conditions were similarly distrib-
ted across groups. Baseline NYHA functional class was
ignificantly better in group 1 compared with groups 2
hrough 4, but no difference was found among groups 2
hrough 4. The logistic EuroScore for AS was higher in the
ow-gradient groups, with highest values in patients with a
ecreased EF.
aseline echocardiography. Tables 2 and 3 show that
AVA, valvular resistance, and LV hypertrophy were similar
among groups with severe AS, but qualitatively worse
compared with moderate AS patients. An inverse relation-
ship with fibrosis (both interstitial and replacement fibrosis)
was found for stroke volume, longitudinal strain rate, and
mitral ring displacement. Valvuloarterial impedance, wall
stress, and E/E= increased across groups 1 through 4. Mitral
ring displacement was closely inversely correlated with the
tissue fibrosis score (measured in percentage per microme-
ter) in biopsy samples and with valvuloarterial impedance
(Fig. 1) but not with EF (r  0.25, p  0.05). Further-
more, a significant but weak correlation was found between
valvuloarterial impedance and tissue fibrosis score in biopsy
samples (r  0.29, p  0.05). Of note, mitral ring
displacement accurately distinguished between groups 1 and
3 using a cutoff value of 9 mm (Fig. 2). By contrast, mean
gradient or EF showed overlapping values. Figure 3 dem-
onstrates an example of a patient with severe AS/low-
gradient/preserved EF, and a characteristic diagnostic
pattern.
Endomyocardial biopsy samples and markers of collagen
metabolism. Myocardial biopsy samples showed a signifi-
cantly higher amount of interstitial fibrosis in groups 3 and
4 compared with group 2 (both p 0.001). Similar findings
were recorded as well for levels of NT-proBNP and
PIIINP, a collagen III degradation product (Table 3). The
tissue fibrosis score was closely correlated with PIIINP and
NT-proBNP (r 0.63 and r 0.69, respectively; both p
0.01).
Baseline cMRI. Baseline cMRI was not feasible in 23
subjects due to claustrophobia (n 18) or implanted devices
(n  5). The distribution of LE-positive segments in the 3
groups is shown in Table 3. In patients in groups 3 and 4,
100% had 1 or more LE-positive segment. By contrast, in
group 2, 47% (n  23) had no LE-positive segment. LE
was mainly observed in the subendocardial layers of the
basal segments. Mitral ring displacement decreased gradu-ally with the increasing number of LE-positive segments on
cMRI (p  0.001 for trend).
Follow-up. All patients with severe AS underwent AVR
(n  49 bioprosthesis; n  20 mechanical valve). Six
patients had cardiac death within the first 30 days (group 2:
n  1 [2%]; group 3: n  2 [18%]; group 4: n  3 [33%]).
In patients with cMRI at follow-up (n  40), no apprecia-
ble change in LE-positive segments 9 months after AVR in
all groups occurred. Echocardiographic follow-up data are
Figure 1 Correlations Between Myocardial Fibrosis
and Functional Parameters
(A) Inverse correlation between biopsy-based assessment of myocardial fibro-
sis (expressed as the percentage of area of fibrosis within the respective sec-
tion) and mitral ring displacement assessed by M-mode echocardiography in
the 4 groups (r  0.79, p  0.0001). (B) Inverse correlation between valvu-
loarterial impedance and mitral ring displacement in the 4 groups (r  0.6;
p  0.001). AS  aortic stenosis; EF  ejection fraction.shown in Table 4 and Figure 4.
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NYHA functional class for each group at baseline and at
follow-up is shown in Tables 1 and 4. In regression analyses
with fixed adjustment for age and sex, NT-proBNP (OR:
5.9 per quartile; 95% CI: 2.5 to 13.5; Wald: 17.0; AUROC:
0.89  0.04; p  0.001) and mitral ring displacement (OR
Figure 2 Scatterplot of Mean Transvalvular Gradient (mm Hg)
Versus Mitral Ring Displacement (mm)
Note that a clear differentiation between moderate AS and severe AS with
low gradients is possible by the assessment of mitral ring displacement.
Abbreviations as in Figure 1.
Figure 3 Patient With a Typical Pattern of Low-Gradient Aortic
A 78-year-old woman from group 3 (ejection fraction 50%) with septal and poster
aortic valve area  0.9 cm2, mean gradient  29 mm Hg. Mitral ring displacement is
diac magnetic resonance imaging. Advanced myocardial fibrosis score is 5.0% and my
mean aortic gradient (mm Hg); AV Vmax  peak aortic velocity (m/s); AV Vmean  mper millimeter: 0.37; 95% CI: 0.23 to 0.59; Wald: 17.4;
AUROC: 0.93  0.03; p  0.0001) were the only markers
ssociated with fibrosis. Of note, the AUROC for age and
ex alone to predict fibrosis was only 0.61  0.07. Both
arkers, NT-proBNP and mitral ring displacement, also
redicted improvement in NYHA functional class after
VR; for NT-proBNP, OR per quartile: 12.2; 95% CI: 3.8
o 38.9; Wald: 17.8; AUROC: 0.92  0.04; p  0.001 and
or mitral ring displacement: OR per millimeter: 0.08; 95%
I: 0.01 to 0.49;Wald: 7.3; AUROC: 0.99 0.01; p 0.007).
y contrast, the AUROC for age and sex alone to predict
utcome was 0.73  0.06. In multivariable analyses, only
itral ring displacement was retained in models for fibrosis
OR: 0.37, 95% CI: 0.23 to 0.58, Wald: 18.9; p  0.0001)
nd functional improvement (OR: 0.09, 95% CI: 0.02 to
.41, Wald: 9.7; p  0.002).
iscussion
here has been some debate about the subset of patients
ith preserved LV EF who present with a low gradient
espite the presence of a small valve area (1,14,15). In
ontrast, some investigators suggested that this pattern may
eflect the presence of a true severe stenosis and more
dvanced stage of disease. Thus, these patients with low-
radient AS and preserved EF represent a major diagnostic
osis
ll of 13 mm, left ventricular end-diastolic diameter of 40 mm, ejection fraction 60%,
(normal value 9 mm). Typical basal septal and lateral late-enhancement on car-
diameter is 13 m. AV maxPG  peak aortic gradient (mm Hg); AV meanPG 
rtic velocity (m/s).Sten
ior wa
6 mm
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ean ao
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July 19, 2011:402–12 Myocardial Fibrosis in Low-Gradient Aortic Valve Stenosisand therapeutic challenge. The current investigation sheds
new light on important functional and morphological char-
acteristics in this challenging group of patients that are
likely to determine patient outcome. The main findings are
that: 1) myocardial longitudinal function is closely related to
a different entity of aortic valve stenosis and transvalvular
gradients with the most severe reduction observed in pa-
tients with low transvalvular gradients; 2) patients with a
Outcome 9 Months After Aortic Valve ReplacementTable 4 Outcome 9 Months After Aortic Valve Replacement
Moderate AS
Clinical outcome
NYHA functional class at follow-up, I/II/III/IV 6/10/1/0
Death 0
Echocardiography
Change in aortic valve area, cm2 0.15 0.2
Change in mean aortic gradient, mm Hg 6 6.4
Change in EF, % 2 6.5
Change in stroke volume, ml·m2 7.5 13.7
Change in LV mass index, g·m2 8.6 29.9
Change in E/E= 0.8 7.0
Change in mitral ring displacement, mm 1.0 1.8
Change in radial strain rate, s1 0.2 0.3
Change in longitudinal septal/lateral strain rate, s1 0.02 0.2
Values are n, n (%), or mean delta values between baseline and follow-up  SD. Data are only giv
versus severe AS/low-gradient AS/EF 50%.
Abbreviations as in Tables 1 and 2.
Figure 4 Baseline and 9-Month Follow-Up of Mitral Ring
Displacement Data According to the 4 Groups Studied
Patients with moderate AS showed higher values both at baseline and fol-
low-up compared with patients with low-gradient AS, irrespective of ejection
fraction. The potential for recovery of mitral ring displacement was best in
patients with severe AS and a high gradient. p  0.05: *versus moderate
AS; †versus severe AS/high gradient; ‡versus baseline. Abbreviations as in
Figure 1.low transvalvular gradient present with more advanced
myocardial fibrosis typically located at the subendocardium
and exhibit a decreased LV stroke volume; 3) both low-
gradient groups with severe AS did not improve signifi-
cantly with respect to global LV function, NYHA func-
tional class, and replacement fibrosis 9 months after AVR;
and 4) the functional parameter of mitral ring displacement
can be measured reliably during standard echocardiography,
capturing the functional consequences of myocardial fibro-
sis; it is related to stroke volume and predicts functional
improvement after AVR.
Impact of myocardial fibrosis on the gradient. In an
experimental setup, Derumeaux et al. (16) proved that an
increased afterload induced by aortic banding causes hypertro-
phy and myocardial fibrosis, which both lead to reduced
myocardial deformation. These changes in LV tissue structure
were closely related to myocardial deformation, whereas the
peak systolic strain rate correlated best with the transmural
extent of myocardial fibrosis (16). Consistent with previous
investigations, the current study showed that myocardial fibro-
sis is a feature of more advanced disease. In this disease stage,
a high level of persistently elevated systolic wall stress and
compromised myocardial perfusion is present (17). As soon as
these intrinsic and extrinsic stressors to the myocardium cannot
be compensated any longer by hypertrophy, they cause myo-
cardial fibrosis. It is predominantly located at the subendocar-
dial layers, leading first to interstitial and later to replacement
fibrosis. The current study demonstrates by the use of endo-
myocardial biopsies (the reference standard for the assessment
of myocardial fibrosis) that especially patients with a low
transvalvular gradient showed a significantly higher degree of
myocardial fibrosis. In addition, replacement fibrosis as a sign
for more advanced fibrosis could be visualized by noninvasive
LE imaging in most of these patients with low transvalvular
vere AS,
Gradient
Severe AS, Low Gradient,
EF >50%
Severe AS, Low Gradient,
EF <50%
14/10/1 0/0/9/0*† 0/0/6/0*†
1 (2) 2 (18)*† 3 (33)*†
.2 0.5* 0.9 0.23* 1.0 0.67*
3 12.3* 21 6.3*† 14 9.6*†
5 11.3 3 7.8 6 18.9
.7 12.9 0.7 7.0 0.2 5.4
.2 46.4* 48.3 29.1* 63.1 54.6*
4 9.9 6 10.3† 6 4.0
.7 1.7 0.7 0.9* 1.6 1.9*
.5 0.5* 0.02 0.6† 0.4 0.3*‡
.2 0.2* 0.1 0.1*† 0.1 0.1
survivors. *p  0.05 versus moderate AS. †p  0.05 versus severe AS/high gradient. ‡p  0.05Se
High
23/
1
4

1
62

1
0
0
en forgradients.
p
p
r
a
t
p
t
t
C
A
e
s
l
t
s
(
p
n
m
w
d
d
b
w
410 Herrmann et al. JACC Vol. 58, No. 4, 2011
Myocardial Fibrosis in Low-Gradient Aortic Valve Stenosis July 19, 2011:402–12It can be assumed that both the decreased longitudinal
function due to fibrotic noncontractile tissue at the subendo-
cardium and a small LV cavity size induced by hypertrophy
lead to a reduced stroke volume and, thus, a low transvalvular
pressure gradient. Accordingly, the group of patients with a
low gradient and a normal EF displayed the smallest LV cavity
size and the highest relative wall thickness. In addition, global
hemodynamics and valve resistance parameters were altered, as
previously reported (18). Thus, stroke volume was reduced and
valvular resistance (a parameter of valve stiffness) was signifi-
cantly increased compared with the high-gradient group.
Additionally, in patients with a low gradient, valvular arterial
impedance was increased because these patients have both
vascular and valvular damage, which indicates a more advanced
stage in disease progression (18). Consistently, serum biomark-
ers for the degradation of collagen (PIIINP) and for myocar-
dial stress (NT-proBNP) were highest in the group of patients
with a low gradient. The latter finding is in good accordance
with the TOPAS (Truly Or Pseudo-severe Aortic Stenosis)
study and a recently published study with a new risk score in
AS, in which patients with lower values of natriuretic peptides
had a better survival and lower mortality risk after AVR (19,20).
With respect to the clinical outcome, our findings con-
firm published data demonstrating that patients with low-
gradient AS are more likely to experience a worse outcome
after AVR (21). Of note, 5 of 6 patients who died during
follow-up were low-gradient patients, whereas 2 had pre-
served EF and 3 had reduced EF. One patient from the
group with severe AS/high gradient died of cardiac arrest.
She was a patient with a high fibrosis tissue score and high
serum levels of PIIINP and NT-proBNP. The relatively
high mortality might be due to the fact that most patients
were severely symptomatic and patients were in an advanced
stage of the disease.
LV function and stenosis severity. Because of the pro-
nounced concentric remodeling, small LV cavities, impaired
LV filling, and impaired longitudinal shortening, some AS
patients may have decreased pump function and thus a low
stroke volume (being also associated with a lower central
venous oxygen saturation), low flow rate, and a low trans-
valvular gradient despite preserved LVEF (1,15). Hence,
this “paradoxical” low-flow, low-gradient AS would be
compatible with a severe AS and more advanced impair-
ment of myocardial function. Other investigators, however,
suggested that this disease pattern is most often due to
inconsistency in the criteria of AVA and gradients proposed
in the guidelines for AS grading and that it generally reflects
moderate or moderate to severe AS (15). The results of the
present study provide important new insight in this regard
and confirm that a substantial proportion of patients with
severe AS may present with low-gradient AS despite the
presence of preserved LVEF.
Current guidelines for the assessment of patients with AS
mention EF as the only established functional parameter
both for the evaluation of the stenosis severity and estima- btion of prognosis (9,10). However, EF seems to have very
little clinical relevance for patients with a low transvalvular
gradient and preserved LV function (i.e., EF 50%)
(3,4,22). This group of patients had severe myocardial
fibrosis and a poor clinical outcome after AVR, and 2 of
them even died during follow-up. EF is mainly determined
by radial function, which can be compensated for a long
time, even in the presence of subendocardial fibrosis (23). It
has been shown that EF will decrease at the very advanced
disease stages, when radial and longitudinal function is
decreased, as present in our last group of patients with a
low-gradient AS and decreased EF (8,19).
In contrast, longitudinal myocardial kinetics as measured
by, for example, longitudinal mitral ring displacement or
tissue Doppler strain or strain rate, is more sensitive for the
detection of subtle LV dysfunction. It is related to suben-
docardial fibers where wall stress is highest and fibrosis
starts in AS. Thus, patients with moderate AS had the best
radial and longitudinal function. Patients with a high-
gradient AS had normal radial and only slightly decreased
longitudinal values. In these patients, the stroke volume was
normal and, thus, the left ventricle could generate a high
transvalvular gradient. In patients with a low gradient but
preserved EF, radial function was almost normal (responsi-
ble for the normal EF), but longitudinal function was
markedly decreased (responsible for the decreased stroke
volume). Only in patients with severe AS and EF 50%
were all functional parameters reduced (EF  radial func-
tion  longitudinal function). Obviously, AVR should be
erformed before the development of this stage of disease
rogression, because the potential for recovery of mitral
ing displacement was best in patients with severe AS and
high gradient (Fig. 4). However, although these pa-
ients with low-gradient AS showed no significant im-
rovement in NYHA functional class, it is known that
hey have a survival benefit after AVR and should not be
reated conservatively (2).
linical impact. Clinical management of patients with
S is mainly based on the assessment of valvular param-
ters, EF, and symptoms (24,25). The current study
uggests that it is also important to carefully assess
ongitudinal myocardial kinetics and LV hemodynamics
o evaluate the stage of the disease and to estimate
hort-term prognosis. Thus, as shown also by others
4,7,8,12,26,27), the presence of low peak velocity or low
eak/mean gradients combined with preserved EF does
ot necessarily indicate the absence of severe stenosis. A
ore comprehensive evaluation is required in patients
ith a small AVA and low gradient.
In the clinical setting in patients with poor echocar-
iographic image quality, it is sometimes difficult to
istinguish between a moderate AS (i.e., low gradient
ecause of no severe valve abnormality) and a severe AS
ith low gradient and preserved EF (i.e., low gradient
ecause of decreased stroke volume). The current data
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July 19, 2011:402–12 Myocardial Fibrosis in Low-Gradient Aortic Valve Stenosisargue for routine assessment of mitral ring displacement
in these patients, which can be conveniently and reliably
acquired in any patient with AS using standard echocar-
diographic methods. Thus, in patients with isolated
low-gradient AS, a cutoff value of 9 mm had an
excellent sensitivity (100%) and specificity (100%) to
distinguish between moderate and severe AS.
Longitudinal myocardial kinetics (e.g., mitral ring dis-
placement, a well-known but infrequently used marker for
myocardial structural abnormalities) captures the functional
consequences of myocardial fibrosis and predicts functional
improvement after AVR. As shown in our previous study,
the mitral ring displacement demonstrates good diagnostic
utility to predict improvement in NYHA functional class in
patients with severe aortic valve stenosis (8). In contrast, an
EF 50% was less predictive. However, the clinical utility
of this promising marker (e.g., in an improved pre-operative
diagnostic algorithm) needs to be investigated in larger
prospective cohorts.
Study limitations. The frequency of patients with severe
S and a low gradient was low, resulting in limited power
f the analyses. This order of magnitude, however, is well
n line with that in the literature in which a prevalence of
ow-flow gradient/severe AS with preserved LV EF of
6% by Doppler echocardiography and 14% by catheter-
zation is reported (1,14). Because of the relatively small
ample size, our findings should be regarded as prelimi-
ary. In particular, the clinical utility of mitral ring
isplacement as a clinically promising surrogate of risk
eeds to be replicated in larger studies. The reference
tandard for the assessment of LV function (i.e., end-
ystolic elastance) was not available, and in a sizable
umber of these older patients (n  18), cMRI was not
feasible because of claustrophobia.
Conclusions
These data suggest that in patients with AS, the devel-
opment of subendocardial fibrosis leads to reduced LV
longitudinal function, which contributes, at least in part,
to the clinically challenging problem of a low transval-
vular gradient with preserved EF. In combination of
clinical parameters such as NYHA functional class, mitral
ring displacement appears to capture the functional
consequences of this type of fibrosis, thus improving the
evaluation of stenosis severity and estimation of progno-
sis. In particular, mitral ring displacement may be useful
to differentiate between moderate AS and low-gradient/
severe AS with preserved EF.
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